Boston Scientific Corporation $BSX Position Trimmed by Lockheed Martin Investment Management Co.

Lockheed Martin Investment Management Co. reduced its position in Boston Scientific Corporation (NYSE:BSX) by 31.4% during the third quarter, HoldingsChannel.com reports. The firm owned 53,160 shares of the medical equipment provider’s stock after selling 24,320 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Boston Scientific were worth $2,320,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in BSX. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific during the first quarter valued at approximately $28,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Boston Scientific during the 1st quarter worth approximately $32,000. Measured Wealth Private Client Group LLC lifted its stake in shares of Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 387 shares during the last quarter. Kelleher Financial Advisors purchased a new position in Boston Scientific during the 2nd quarter valued at $25,000. Finally, Nvwm LLC boosted its holdings in Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 542 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BSX shares. Rothschild & Co Redburn cut their price objective on Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Stifel Nicolaus decreased their target price on Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, October 26th. Sanford C. Bernstein lowered their target price on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a research note on Thursday, October 29th. Royal Bank Of Canada cut their price target on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Finally, Leerink Partners cut their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $61.43.

Boston Scientific Trading Up 2.9%

BSX opened at $44.00 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. The stock’s fifty day moving average is $44.26 and its two-hundred day moving average is $55.46. The company has a market capitalization of $63.78 billion, a P/E ratio of 18.64, a PEG ratio of 1.36 and a beta of 0.60. Boston Scientific Corporation has a 52 week low of $39.57 and a 52 week high of $105.65.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the prior year, the business earned $0.75 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Analysts forecast that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.